Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

  |  Issue: October 2021  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. News release: Xeljanz (tofacitinib citrate) receives marketing authorization in the European Union for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis. Pfizer Inc. 2021 Aug 20.
  2. Juvenile idiopathic arthritis. Mayo Clinic. 2021.
  3. Juvenile idiopathic arthritis. The Arthritis Foundation. 2021.
  4. Efficacy study of tofacitinib in pediatric JIA population (NCT02592434). ClinicalTrials.gov. 2020 Apr 13.
  5. Brunner H, Synoverska O, Ting T, et al. Tofacitinib for the treatment of polyarticular course juvenile idiopathic arthritis: Results of a phase 3 randomized, double-blind, placebo-controlled withdrawal study [abstract: L22]. Arthritis Rheumatol. 2019 Oct; 71(suppl 10).

Related Articles
    Oksana Kuzmina/shutterstock.comx

    Environmental Factors in Pediatric Systemic Autoimmune Diseases

    Systemic autoimmune diseases are thought to result from immune dysregulation in genetically susceptible individuals who were exposed to environmental risk factors. Many studies have identified genetic risk factors for these diseases, but concordance rates among monozygotic twins are 25–40%, suggesting that nonheritable environmental factors play a more prominent role.1,2 Through carefully conducted epidemiologic and other…

    The Heterogeneity of Psoriatic Arthritis

    SAN DIEGO—Differences between psoriatic arthritis and rheumatoid arthritis highlight the need for the development of imaging modalities, laboratory tests and other biomarkers that are explored and validated specifically for PsA to advance the goal of personalized or precision medicine. In this article, expert David S. Pisetsky, MD, PhD, explores the top research in psoriatic arthritis presented at ACR Convergence 2023.